BioPharma Dive Feb 27, 2026 Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
BioPharma Dive Feb 26, 2026 Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
BioPharma Dive Feb 25, 2026 Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
BioPharma Dive Feb 24, 2026 Novo, searching for a spark, spotlights new data for three-pronged obesity drug